Scancell (LON:SCLP) Stock Price Down 3.2% - Here's Why

Key Points

• Shares of Scancell Holdings plc dropped by 3.2% during mid-day trading, with the stock trading as low as GBX 9.60 ($0.13).
• The company has a market cap of £100.51 million and a price-to-earnings ratio of -465.63, indicating significant financial challenges.
• Insider Martin Diggle purchased 102,236 shares at an average price of GBX 11 per share, demonstrating confidence in the company's future despite the current stock decline.

Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price dropped 3.2% during mid-day trading on Tuesday . The stock traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). Approximately 1,336,894 shares were traded during mid-day trading, an increase of 44% from the average daily volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.13).

Scancell Stock Performance

The company has a market cap of £92.09 million, a P/E ratio of -426.63 and a beta of 0.35. The firm has a 50 day moving average of GBX 10.15 and a 200-day moving average of GBX 9.63. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Insider Activity at Scancell

In related news, insider Martin Diggle purchased 4,400,000 shares of Scancell stock in a transaction dated Friday, August 1st. The stock was purchased at an average cost of GBX 10 per share, with a total value of £440,000. Insiders own 15.15% of the company's stock.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.